Staar Surgical's sales grew, but it delivered mixed signals on profitability.

STAAR Surgical (NASDAQ:STAA) rose 6.5% amid some takeover speculation. The maker of implantable lenses is said to have been ...

Staar Surgical (STAA – Research Report), the ... particularly in key markets such as the U.S. and China. Management has reiterated its guidance for FY24, but has lowered expectations for growth ...

Anthony Petrone has given his Buy rating due to a combination of factors including Staar Surgical’s robust performance in Japan and EMEA, which counterbalanced challenges in the US and China ...

S&P 500 funds are inexpensive and share many similarities, but you'll find small differences in cost and how closely they track their benchmark.

Staar Surgical STAA will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Staar Surgical to ...

Operator: Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As a reminder, this event is being ...

Morgan Stanley has downgraded STAAR Surgical (NASDAQ ... bank said slower growth estimates in China mid-term “leave US HSD ...

For those of us with low-grade serous ovarian cancer (LGSOC ... States dedicated to improving outcomes for the disease — STAAR Ovarian Cancer Foundation. The acronym stands for “Survive.

Staar Surgical (STAA) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.30 per share a year ago.

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...